ClinicalTrials.gg
CompletedNCT04336124Updated Nov 28, 2022

Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients

A Phase 1 interventional study of CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule) in Advanced Cancer, sponsored by TaiRx, Inc.. Completed at 2 sites in Taiwan. Open to participants aged 20 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-11-28.

Sponsored by TaiRx, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2021, 5 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
20 Years to 99 Years
Sex
All
01

Study summary

CVM-1118 Immediate-release (IR) Capsule and CVM-1118 Extended-release (ER) Capsule are proprietary oncology products developed by TaiRx, Inc. for the treatment of patients suffering from advanced cancer. Due to the short elimination half-life of CVM-1118 IR capsules, the extended release (ER) formulation, containing mini-tablets in hard capsule, has been developed to prolong the drug absorption and longer exposure after oral administration. The designed dose of CVM-1118 ER was 200 mg per capsule to provide a more patient-compliant and safe dosage of CVM-1118. The clinical study CVMEX-001 is therefore designed to evaluate the safety and pharmacokinetics of CVM-1118 extend release (ER) Capsule (200 mg/capsule) in patients with advanced cancer.

Read the detailed description

The CVM-1118 ER Capsule will be orally administered BID or TID before meal in 28-day treatment cycles. Patients will receive 400, 600, 800 to 1,200 mg of CVM-1118 ER Capsule in sequential cohort based on safety and dose tolerability. A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day. Within the first two cohorts, if any Grade 2 or greater toxicity at least possibly attributable to CVM-1118 ER capsule is reported in the first patient during first cycle, a single-patient cohort will be converted to conventional 3+3 study design once and expand to a minimum of 3 evaluable patients for assessment of toxicity within the first cycle. Dose escalation will occur until DLT occurs in 2 or more patients within a dose level. In any cohort, if 1 patient experiences a DLT, 3 additional patients will be enrolled to that dose level. If 2 or more patients experience a DLT, no further dose escalation will occur. Plasma pharmacokinetics samples will be collected at pre-determined time-points for all patients participating in the dose-escalation study.

This study will be completed and closed once the MTD is determined for CVM-1118 ER capsules. However, at the end of 4 cycles, it is recommended that some patients should continue receiving the clinical benefit from CVM-1118 ER capsules. Thus, patients may be continuously treated at the assigned dose level or next higher dose level provided it has been shown to be safe in a previously treated cohort by safety committee, until the treating physician feels the patient is no longer benefiting from the treatment, or CVM-1118 ER Capsule becomes commercially available, as applicable in the country in which the patient lives. In the event of unacceptable toxicity at a given dose, CVM-1118 can be reduced to the previous dose level or suggested lower dose by PI. If unacceptable toxicity persists despite 2 dose reductions, the patient should be removed from study.

02

Conditions studied

  • Advanced Cancer

Browse trials for

Keywords

  • Oncology
  • Advanced Solid Malignancy
  • Tumor Response
  • Safety and pharmacokinetics
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 5 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

TaiRx, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Tumor eligibility:

    or cytologically confirmed advanced , which is to standard of care therapy, or for whom no standard of care therapy is available.

  2. Solid tumors must have measurable or evaluable disease as per (RECIST v. 1.1). Target lesions that have been previously irradiated will not be considered measurable (lesion) unless increase in size is observed following completion of radiation therapy. Lymphomas must have as per Revised Response Criteria for Malignant Lymphomas.
  3. performance status 0 to 2. Resolution of all acute toxic effects of prior therapy or surgical procedures to grade 1 (except alopecia).
  4. Adequate organ function as defined by the following criteria:

    1. Serum (AST) and serum alanine transaminase (ALT) ≤3 x (ULN), or AST and ALT ≤5 x ULN if liver function abnormalities are due to underlying malignancy
    2. Total serum ≤1.5 x ULN (except for patients with documented Gilbert's syndrome)
    3. (ANC) 1,500/µL
    4. 90,000/µL
    5. 9.0 g/dL
    6. Serum creatinine ≤1.5 x ULN or of ≥ 60 mL/min
  5. Signed and dated document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the study prior to enrollment.
  6. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients presenting with any of the following will not be included in the study:

    1. Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of starting study treatment.
    2. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue except for patients with lymphoma
    3. Current treatment on another clinical study.
    4. , spinal cord compression, carcinomatous meningitis, or unless appropriately treated and neurologically stable for at least 4 weeks.
  2. Any of the following within 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including ; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and sponsor, the 6-month post-event-free period for a patient with a pulmonary embolus can be waived if due to advanced cancers. Appropriate treatment with anticoagulants is permitted.
  3. Hypertension that cannot be controlled by medications (>160/100 mmHg despite optimal medical therapy).
  4. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily is allowed).
  5. Known infection.
  6. virus (HBV) or virus (HCV) with evidence of chronic active disease or receiving/requiring antiviral therapy.
  7. History of receiving organ transplantation or immune disorders that require continuous agent therapy.
  8. Pregnancy or breastfeeding. Female patients must be surgically sterile or be or must agree to the use of effective during the period of therapy. All female patients with must have a negative pregnancy test (serum or urine) prior to enrollment. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  9. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    CVM-1118 ER

    Dose escalation (escalation from 400, 600, 800 to 1200 mg of CVM-1118 ER Capsule)

    Drug: CVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)

Interventions

  • DrugCVM-1118 Extended-Release (ER) Capsules (200 mg/capsule)

    Drug page: Foslinanib

    Patients will receive initial dose regimen: 400 mg of CVM-1118 ER Capsule per day (200 mg BID) in a 28-day cycle for 4 cycles. Dose escalates from 400, 600, 800, to 1200 mg of CVM-1118 ER capsules with either BID or TID dosing. A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day. If 2 or more patients experience a DLT, no further dose escalation will occur.

    Also known as: TRX-818 ER

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT) of CVM-1118 ER Capsule

    Dose escalation will occur until DLT occurs in 2 or more patients within a dose level. In any cohort, if 1 patient experiences a DLT, 3 additional patients will be enrolled to that dose level. If 2 or more patients experience a DLT, no further dose escalation will occur.

    Time frame: up to 28 days

  2. Maximum tolerated dose (MTD) of CVM-1118 ER Capsule

    The MTD will be defined as the dose level at which at most one of six patients experiences a DLT after 28 days of treatment have occurred, with the next higher dose having at least 2/3 or 2/6 patients experiencing a DLT. The Safety Committee may expand the cohort beyond six patients to better define the safety profile of this cohort in the search for the MTD.

    Time frame: up to 28 days

Secondary outcomes

  1. Preliminary assessment of anti-tumor activity of CVM-1118 ER Capsule

    RECIST 1.1 for solid tumor and Revised Response Criteria for Malignant Lymphoma

    Time frame: up to 56 days

  2. Measure of plasma pharmacokinetic (PK) profiles of CVM-1118 and its metabolite CVM-1125 to include AUC(0-last)

    AUC(0-last): area under the plasma concentration versus time curve to the time of the last measurable concentration

    Time frame: Cycle 1 Day 1 and Day 15: pre-dose, 2, 3.5, 5, 7, 9, and 12 hours post dose

  3. Measure of plasma pharmacokinetic (PK) profiles of CVM-1118 and its metabolite CVM-1125 to include Cmax

    Cmax: Maximum plasma concentration

    Time frame: Cycle 1 Day 1 and Day 15: pre-dose, 2, 3.5, 5, 7, 9, and 12 hours post dose

  4. Measure of plasma pharmacokinetic (PK) profiles of CVM-1118 and its metabolite CVM-1125 to include Tmax

    Tmax: Time to maximum plasma concentration

    Time frame: Cycle 1 Day 1 and Day 15: pre-dose, 2, 3.5, 5, 7, 9, and 12 hours post dose

  5. Measure of plasma pharmacokinetic (PK) profiles of CVM-1118 and its metabolite CVM-1125 to include T(1/2)

    T(1/2): Terminal elimination half-life

    Time frame: Cycle 1 Day 1 and Day 15: pre-dose, 2, 3.5, 5, 7, 9, and 12 hours post dose

  6. Time to tumor progression (TTP)

    Time to progression (TTP) is defined as the time from the first dose of study drug to the time of progression

    Time frame: up to 112 days

07

Study locations

2 sites
  • China Medical University Hospital
    Taichung, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Feb 2021, 8 months.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 8 months is below that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2020
First posted
Apr 7, 2020
StartActual
May 25, 2020
Primary completionActual
Feb 8, 2021
CompletionActual
Apr 8, 2022
Last update
Nov 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04336124
Lead sponsor
TaiRx, Inc.
Responsible party
Sponsor
First posted
Apr 7, 2020
Start date
May 25, 2020
Primary completion
Feb 8, 2021
Completion
Apr 8, 2022
Last update
Nov 28, 2022

Study contacts

Wu-Chou Su, M.D.
principal investigator · National Cheng Kung University Hospital,Taiwan
Li-Yuan Bai, M.D.
principal investigator · China Medical University Hospital,Taiwan

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Foslinanib

Start the discussion